A 35-year-old man with newly diagnosed generalized tonic-clonic epilepsy (2 seizures in 3 weeks) is started on levetiracetam 500 mg twice daily. After 2 weeks, he reports severe mood changes, irritability, and suicidal ideation. He has no prior psychiatric history. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has developed **acute behavioural and mood changes** (irritability, suicidal ideation) shortly after initiating levetiracetam. This is a recognized adverse effect that requires prompt recognition and action. ## Levetiracetam and Neuropsychiatric Adverse Effects **High-Yield:** Levetiracetam is associated with neuropsychiatric side effects in approximately 10–15% of patients, including: - Mood changes (irritability, aggression, depression) - Suicidal ideation and behaviour - Anxiety and personality changes - Psychosis (rare) **Key Point:** These effects can emerge within days to weeks of initiation and are dose-dependent. The FDA issued a black-box warning for suicidality risk with AEDs [cite:FDA 2008 AED Warning]. ## Management of AED-Induced Neuropsychiatric Toxicity **Clinical Pearl:** The standard approach is: 1. **Recognize and document** the temporal relationship between AED initiation and psychiatric symptoms 2. **Discontinue the offending agent** — continuing levetiracetam with psychiatric symptoms is unsafe 3. **Switch to an alternative AED** with lower neuropsychiatric risk: - **Lamotrigine** — mood-stabilizing properties; lower psychiatric side-effect profile - **Oxcarbazepine** — structurally similar to carbamazepine; fewer psychiatric effects than levetiracetam - **Valproate** — avoid if possible (teratogenicity, hepatotoxicity); not first-line for mood issues 4. **Refer to psychiatry** for concurrent mood assessment and management ## Why Not Continue Levetiracetam? **Warning:** Continuing levetiracetam while adding an SSRI (sertraline) does NOT address the root cause — the levetiracetam itself is the culprit. Masking psychiatric symptoms with an antidepressant while the offending drug remains is unsafe and ineffective. The patient has **suicidal ideation**, which is a serious safety concern. ## Decision Algorithm ```mermaid flowchart TD A[AED-induced neuropsychiatric toxicity<br/>Suicidal ideation + levetiracetam]:::urgent --> B{Severity?}:::decision B -->|Mild irritability| C[Reduce dose or monitor]:::action B -->|Moderate-severe mood change<br/>or suicidal ideation| D[Discontinue offending AED]:::action D --> E[Switch to alternative AED<br/>Lamotrigine or oxcarbazepine]:::action E --> F[Refer to psychiatry]:::action F --> G[Mood assessment & management]:::action ``` ## AED Comparison for Neuropsychiatric Safety | AED | Neuropsychiatric Risk | Mood Effect | First-Line for Generalized GTCS | |-----|----------------------|-------------|--------------------------------| | Levetiracetam | High (10–15%) | Negative | Yes, but watch for mood | | Lamotrigine | Low | Mood-stabilizing | Yes (especially if mood concerns) | | Oxcarbazepine | Low–moderate | Neutral | Yes | | Valproate | Moderate | Variable | Yes, but teratogenic | | Carbamazepine | Moderate | Neutral | Yes | ## Seizure Coverage During Switch **Key Point:** Ensure overlap during the transition: - Continue levetiracetam at therapeutic dose while titrating the new AED to therapeutic levels - Once the new AED reaches effective dose, taper levetiracetam over 1–2 weeks - This prevents breakthrough seizures during the switch